Trending Antitrust Issues in Pharmaceuticals and Life Sciences
Created on February 21, 2019
The pharmaceutical and life sciences market has long been a focus for antitrust enforcers, litigants, and academics. A lack of transparency into pricing, combined with a complex distribution chain, the presence of third party payers, and a nuanced regulatory scheme, have all contributed to the rise of antitrust concerns in this area. As pharmaceutical pricing continues to dominate political and legislative debates, media reports, and even everyday conversations between consumers, antitrust law is slated to play an even larger role than before in shaping the industry for the foreseeable future.
In this course, Jeff Bank, a partner in the Antitrust Group at Wilson Sonsini Goodrich & Rosati, PC, explains why antitrust is perceived by some as a solution to rising healthcare costs, reviews recent litigation and enforcement in the industry, and provides practical guidance to consider when counseling clients.
- Explore why unique aspects of the pharmaceuticals and life sciences industry have led to challenging antitrust disputes
- Examine recent litigation and enforcement actions and forecast future trends
- Identify strategies for counseling clients on best business practices and litigation opportunities
Gain access to this course, plus unlimited access to 1,500+ courses, with an Unlimited Subscription.Explore Lawline Subscriptions